Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group.
about
Natriuretic Peptide testing in primary carebeta-blockers in heart failure: recently completed and ongoing clinical trials.Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease.Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspectives.Surrogate end points in heart failure.B-type natriuretic peptide in ischemic heart disease.Alterations of serum brain type natriuretic peptide (BNP) in patients with Crimean-Congo hemorrhagic feverN-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure.NT-proBNP in heart failure: therapy decisions and monitoring.B-type natriuretic peptide: practical diagnostic use for evaluating ventricular dysfunction.BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases.The ability of heart failure specialists to accurately predict NT-proBNP levels based on clinical assessment and a previous NT-proBNP measurement.Natriuretic peptide C receptor signalling in the heart and vasculature.Serial monitoring of brain natriuretic peptide concentrations for drug therapy management in patients with chronic heart failure.B-type natriuretic peptides: prognostic markers in stable coronary artery disease.The Importance of Amino-terminal pro-Brain Natriuretic Peptide Testing in Clinical Cardiology.Biomarkers in heart failure: a clinical review.Natriuretic peptides in heart failure: should therapy be guided by BNP levels?Natriuretic peptides: Diagnostic and therapeutic use.Changes in plasma atrial natriuretic peptide after angiocardiography.Late night thoughtsEffect of beta-blockade on autonomic modulation of heart rate and neurohormonal profile in decompensated heart failure.Carvedilol increases plasma vascular endothelial growth factor (VEGF) in patients with chronic heart failure.Neurohumoral prediction of left-ventricular morphologic response to beta-blockade with metoprolol in chronic left-ventricular systolic heart failure.Atenolol improves ventricular function without changing plasma noradrenaline but decreasing plasma atrial natriuretic factor in chronic heart failure.Basal and exercise-induced neuroendocrine activation in patients with heart failure and in normal subjects.BNP and ANP as diagnostic and predictive markers in heart failure with left ventricular systolic dysfunction.The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine.Combination of B-type natriuretic peptide levels and non-invasive hemodynamic parameters in diagnosing congestive heart failure in the emergency department.Rationale and design of the cardiac magnetic resonance imaging substudy of The ONTARGET Trial Programme.Carvedilol in dogs with dilated cardiomyopathy.Carvedilol exerts more potent antiadrenergic effect than metoprolol in heart failure.Brain natriuretic peptide: does it play a role in post-cardiac surgery patients?Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure.Plasma brain natriuretic peptide after long-term treatment for heart failure in general practice.Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension.Effects of immunoadsorption on the nt-BNP and nt-ANP plasma levels of patients suffering from dilated cardiomyopathy.B-type natriuretic peptides: applications for heart failure management in 2005.Risk prediction in acute coronary syndrome from serial in-hospital measurements of N-terminal pro-B-type natriuretic peptide.
P2860
Q33572286-156DB8D5-3D5D-4E87-B6C4-143374D0ED8DQ34074729-39169883-1FB4-4AEA-8A58-D2E5E9C7DB9FQ34241396-5CE35111-D2DC-4020-87B7-8FEFCFD5C45BQ34448373-B36BAFB4-0FD1-4369-945C-29B455FF9F2CQ34564309-01159134-C83B-432A-88DF-FCE36B7011BCQ35152072-3FBA3E20-1421-4A5A-848E-77F308D35EFEQ35481345-B8864F82-6A6B-4C52-8FF8-7526C526D548Q35581367-16C6DA96-FACB-4426-B0FB-B7D4ECDE72BFQ35677310-2CD927D3-23E1-47C8-B7D6-0D4DEBC2E18BQ35796786-0AB24952-2EDA-4157-8E85-378182149F18Q35987052-0E9C226A-1C09-4D03-B1B3-40B970792730Q36944131-31DE8EAA-78F7-46E0-B705-7A0B766996B9Q37002318-8E0BB6F4-BC1B-4588-9C92-F62B272ADD90Q37092258-55F4FB59-61AF-4379-9633-905830006EB0Q37118998-0ADB8F11-B892-44F8-A6AC-26357B65E248Q37277937-D30A8A8E-0257-42AA-B9CE-33BCEC9FD597Q37339808-6C0BE08B-1BF8-48A7-8833-B8CE447A545BQ37638155-98A3F331-88D7-43E6-AE84-C3455CAB3B8FQ39581832-CF10FD98-91CC-4313-98DF-73371369BD8FQ40169964-D16059D2-0AFA-4A99-B5E8-21FC5E508254Q40489360-DFB801B7-7E9E-4660-BACC-8C73FD815872Q43595374-67A565D7-D370-48E0-BD82-C8704F4A7F64Q43621188-99D31AF5-3787-4579-9B6B-0F2F278A89F1Q44202914-196755AC-C615-40C7-B399-AE352AE7E573Q44515710-F0CE65FC-62F8-425B-ADE4-623AE062EAE7Q44794225-18D669AC-3FA6-4548-870A-8D5922566A0FQ45139069-54C564FB-A029-4F79-BD5F-4065AE988655Q46515116-B1D899CD-9A32-4B73-88C5-3418DF1C4FB2Q46561355-E20C9DDB-BAB1-4AA8-9545-597B4ECB2B76Q46750958-B3843BE6-CEB4-40E3-A532-93A865442579Q46807342-286BF8EF-32CA-4CBC-9525-9D25A9F28FD1Q46871343-CE2D4D8A-D123-49E8-BEA2-9E7D2C049B38Q48259553-65BA4A4B-38C7-41F3-9B06-7042158C7BCCQ48399609-CFAEBBA5-A38D-41B7-AFB7-C571323A83A1Q48518324-C7BEB6D8-587C-4C64-92E1-9DD11720453EQ48550363-BCCBDDC5-2029-4487-8CEF-3CA6C6CEFB97Q48607244-B430F2A4-9486-4E53-AF11-1C9C4BF7AB6EQ48853087-0A5DF65A-2AF0-4EAE-9754-37286AA2752FQ49111539-26405192-B37F-4CFC-9B6B-AD27514CF3F3
P2860
Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Neurohumoral prediction of ben ...... w Zealand Heart Failure Group.
@en
Neurohumoral prediction of ben ...... w Zealand Heart Failure Group.
@nl
type
label
Neurohumoral prediction of ben ...... w Zealand Heart Failure Group.
@en
Neurohumoral prediction of ben ...... w Zealand Heart Failure Group.
@nl
prefLabel
Neurohumoral prediction of ben ...... w Zealand Heart Failure Group.
@en
Neurohumoral prediction of ben ...... w Zealand Heart Failure Group.
@nl
P2093
P921
P356
P1433
P1476
Neurohumoral prediction of ben ...... w Zealand Heart Failure Group.
@en
P2093
A M Richards
C Frampton
E A Espiner
M G Nicholls
S Macmahon
T G Yandle
P304
P356
10.1161/01.CIR.99.6.786
P407
P577
1999-02-01T00:00:00Z